HBM Holdings Ltd. Interim Results: Revenue Surges to US$101.3 Million, Net Profit Jumps to US$73.0 Million, Basic EPS at US$0.09 for First Half of 2025
Reuters
Sep 26, 2025
HBM Holdings Ltd. Interim Results: Revenue Surges to US$101.3 Million, Net Profit Jumps to US$73.0 Million, Basic EPS at US$0.09 for First Half of 2025
HBM Holdings Ltd. reported its interim results for the six months ended 30 June 2025. Revenue for the period was US$101.3 million, compared to US$23.7 million in the same period of 2024. Profit for the period reached US$73.0 million, up from US$1.4 million in the prior-year period. Diluted earnings per share were US$0.09, compared to US$0.00 in the previous year. Cash and cash equivalents stood at US$320.7 million as of 30 June 2025, compared to US$166.8 million at 31 December 2024. Total assets increased to US$380.5 million from US$215.0 million at year-end 2024, while total equity rose to US$283.6 million from US$124.1 million. During the reporting period, HBM Holdings entered a global strategic collaboration with AstraZeneca to develop multi-specific antibodies in immunology, oncology, and other areas. As part of the agreement, AstraZeneca acquired 9.15% of newly issued shares of Harbour BioMed for US$105 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief on September 26, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.